Merck Reports Positive Phase 3 Results for Enlicitide In Treating Adults With Hyperlipidemia

Merck & Co Inc MRK:

• MERCK ANNOUNCES POSITIVE TOPLINE RESULTS FROM THE FIRST TWO PHASE 3 CORALREEF TRIALS EVALUATING ENLICITIDE DECANOATE FOR THE TREATMENT OF ADULTS WITH HYPERLIPIDEMIA

• MERCK & CO INC - ENLICITIDE SHOWS SIGNIFICANT LDL-C REDUCTIONS IN PHASE 3 TRIALS

• MERCK & CO INC - CORALREEF TRIALS MEET PRIMARY AND SECONDARY ENDPOINTS